Psoriasis and multiple sclerosis (MS) are both considered T cell-mediated diseases, with similarities in the pathophysiology.To our knowledge, only a case of severe disseminated psoriasis eruption has been described during natalizumab treatment [3]. We describe a patient affected by relapsing remitting (RR)MS with new-onset psoriatic arthritis during natalizumab treatment. In conclusion, taking into account the possible genetic susceptibility for cutaneous autoimmune diseases, we believe that it is important to investigate not only personal, but also family history for autoimmune comorbidities, to select the most suitable disease-modifying treatment for each MS patient.
Vacchiano, V., Foschi, M., Sabattini, L., Scandellari, C., Lugaresi, A. (2018). Arthritic psoriasis during natalizumab treatment: a case report and review of the literature. NEUROLOGICAL SCIENCES, 39(1):181-183(1), 181-183 [10.1007/s10072-017-3112-5].
Arthritic psoriasis during natalizumab treatment: a case report and review of the literature
Vacchiano, V.;LUGARESI, ALESSANDRA
2018
Abstract
Psoriasis and multiple sclerosis (MS) are both considered T cell-mediated diseases, with similarities in the pathophysiology.To our knowledge, only a case of severe disseminated psoriasis eruption has been described during natalizumab treatment [3]. We describe a patient affected by relapsing remitting (RR)MS with new-onset psoriatic arthritis during natalizumab treatment. In conclusion, taking into account the possible genetic susceptibility for cutaneous autoimmune diseases, we believe that it is important to investigate not only personal, but also family history for autoimmune comorbidities, to select the most suitable disease-modifying treatment for each MS patient.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
